A 59-year-old man in Switzerland was bitten by a West African green mamba, a slender tree-dwelling elapid whose natural range lies in the coastal forests of West Africa. The bitten limb swelled. Then the weakness set in, and it kept climbing until he could no longer breathe on his own.

The case, reported by emergency and intensive care physicians at Lausanne University Hospital with a toxicologist from a French military hospital, is a study in what happens when a snake from one continent bites someone on another. It was published in Toxicon.

An African Elapid Envenomation in a European City

Mamba venom is dominated by toxins that interfere with signaling between nerve and muscle. In this patient, the neurotoxic syndrome dominated, producing progressive weakness that advanced to respiratory failure alongside swelling of the bitten limb.

Bites like this are rare in Europe and the United States, but the authors described them as a growing medical concern driven by the popularity of keeping exotic reptiles in high-income countries. Most physicians will never manage one, which is precisely the problem.

Snakebite remains a major cause of death globally. The World Health Organization estimates that envenoming kills up to 138,000 people a year and leaves about 400,000 more with permanent disabilities, concentrated overwhelmingly in rural parts of Africa, Asia and Latin America rather than in European intensive care units.

Doctors Borrowed a Monitor from the Operating Room

The clinically unusual element here was not the snake. It was the instrument the team reached for.

After giving antivenom, the clinicians used quantitative neuromuscular stimulation, commonly called train-of-four monitoring, to assess how well signals were crossing from nerve to muscle. Anesthesiologists use the same device routinely to confirm that paralytic drugs have worn off before a patient is woken up.

Applying it to venom-induced blockade is an improvisation, and the authors treated it as one. They presented it as a question worth studying rather than a validated practice. Whether the readings reliably track ongoing venom activity is unknown, and that uncertainty rests on a single patient.

Finding the Antivenom Is Often Harder Than Giving It

The authors devoted much of their report to logistics rather than pharmacology, and that emphasis is the point. Managing an exotic snakebite means recognizing when antivenom is indicated, identifying which product covers the species, locating a supply that may sit hundreds of miles away, and arranging transport under cold-chain conditions while the patient deteriorates.

They argued that a syndromic approach, identifying the species where possible, and coordination among emergency physicians, intensivists, surgeons, pharmacists, and snakebite experts are all essential. Because these cases are so rare, hospitals need a defined management strategy and reliable reference material worked out in advance rather than improvised at 3 a.m. Antivenom is also not interchangeable. A product raised against one genus may do nothing for another, and specificity, dosing, storage temperature, and the risk of allergic reaction all have to be weighed while the clock runs.

Switzerland already sees a steady trickle of these events. An earlier Swiss report noted that roughly 80 exotic snakebite cases were recorded by the Swiss Poisons Information Centre over a decade. That series is also a reminder that outcomes vary widely even within one species. Its patient was bitten by green mambas on three separate occasions and developed severe local swelling, including compartment syndrome that required surgery, but little in the way of neurological signs.

The Same Scenario Plays Out in American Emergency Rooms

U.S. poison centers log between 33 and 50 non-native venomous snakebites a year. A retrospective analysis of the National Poison Data System published in Toxins counted 258 human exposures to exotic venomous snakes over seven years, an average of 37 a year, involving at least 61 distinct species. Seventy percent of those bites happened in a private residence. About 35 percent of patients received antivenom. Seventy-nine percent of the people bitten were men, and the average age was 33, but 16 percent were under 20, which the authors read as evidence that household members of private collectors share the risk.

American clinicians solve the sourcing problem through the Antivenom Index, a database maintained by the Association of Zoos and Aquariums that lets a treating hospital find out which accredited zoo or aquarium stocks the product it needs. The system has an obvious limit. Zoos stock antivenom only for the snakes in their own collections, so a species nobody exhibits may have no domestic supply at all. A Florida case report describes the workflow in action. A man bitten by his own Sri Lankan green pit viper received six vials of a Thai polyvalent antivenom, located through the Index and sourced from a local antivenom bank, five hours after the bite. He was discharged in good condition after 26 hours of observation. When no FDA-approved product exists, the agency permits emergency use of unlicensed foreign antivenoms through its investigational new drug pathway.

For the small population this affects, mostly private keepers and staff who work with venomous reptiles, the practical implications are consistent across every published report. Do not handle venomous species alone. Call a poison center immediately rather than waiting for symptoms to declare themselves. And know the exact species, because the answer determines which vial has to be found and how fast.

Key Questions Answered

What is a West African green mamba?

Dendroaspis viridis is a slender, tree-dwelling elapid native to coastal West Africa. Its venom acts mainly on the connection between nerve and muscle and can cause paralysis.

What happened to the patient?

The 59-year-old man developed swelling of the bitten limb followed by progressive weakness that advanced to respiratory failure. He required intensive care management and antivenom.

Why was this case difficult for the hospital?

European clinicians rarely encounter exotic envenomation. The report describes challenges in deciding when antivenom is indicated, matching a product to the species, and getting that product to the patient quickly.

What was the train-of-four monitor doing there?

It is normally used in anesthesia to check whether paralytic drugs have worn off. The team applied it after antivenom to track neuromuscular transmission, an approach the authors called unproven for this purpose.

What should a keeper do after a bite?

Contact a poison center immediately and get to an emergency department, with the exact species identified if possible, since antivenom selection and sourcing depend entirely on that information.